Magd A Kotb1. 1. Department of Pediatrics, Cairo University, PO Box, 85 El Mokatam, Cairo 11571, Egypt. magdkotb@hotmail.com
Abstract
BACKGROUND: Ursodeoxycholic acid is a bile acid that was found to increase bile flow, protect hepatocytes, and dissolve gallstones. PURPOSE: The objective of this study is to review ursodeoxycholic acid in infants and children with extrahepatic biliary atresia. METHODS: We used a statistical analysis of data of records of infants and children having extrahepatic biliary atresia who underwent Kasai portoenterostomy and attended Hepatology Clinic, New Children's Hospital, Cairo University, Egypt, from May 1985 until June 2005. RESULTS: Of 141 infants with extrahepatic biliary atresia, 108 received ursodeoxycholic acid for mean duration +/- SD of 252.6 +/- 544.9 days in a dosage of 20 mg/kg per day. The outcome of infants who did not receive ursodeoxycholic acid and those who did was the following: 8 (24.2%) and 11 (10.18%) had a successful outcome (P = .043), 0 (0%) and 7 (6.4%) improved (P = .148), 25 (75.7%) and 84 (77.7%) had a failed outcome (P = .489), and none vs 5 died (4.6%) (P = .135), respectively. The predictors of successful outcomes were age less than 65 days at portoenterostomy (P = .008) and absence of ursodeoxycholic acid intake (P = .04) with a likelihood of a successful outcome that was 2.8, that associated with ursodeoxycholic acid intake. CONCLUSION: In this cohort of infants with extrahepatic biliary atresia, ursodeoxycholic acid was not shown to be effective, and its use was associated with a plethora of hepatic and extrahepatic complications.
BACKGROUND:Ursodeoxycholic acid is a bile acid that was found to increase bile flow, protect hepatocytes, and dissolve gallstones. PURPOSE: The objective of this study is to review ursodeoxycholic acid in infants and children with extrahepatic biliary atresia. METHODS: We used a statistical analysis of data of records of infants and children having extrahepatic biliary atresia who underwent Kasai portoenterostomy and attended Hepatology Clinic, New Children's Hospital, Cairo University, Egypt, from May 1985 until June 2005. RESULTS: Of 141 infants with extrahepatic biliary atresia, 108 received ursodeoxycholic acid for mean duration +/- SD of 252.6 +/- 544.9 days in a dosage of 20 mg/kg per day. The outcome of infants who did not receive ursodeoxycholic acid and those who did was the following: 8 (24.2%) and 11 (10.18%) had a successful outcome (P = .043), 0 (0%) and 7 (6.4%) improved (P = .148), 25 (75.7%) and 84 (77.7%) had a failed outcome (P = .489), and none vs 5 died (4.6%) (P = .135), respectively. The predictors of successful outcomes were age less than 65 days at portoenterostomy (P = .008) and absence of ursodeoxycholic acid intake (P = .04) with a likelihood of a successful outcome that was 2.8, that associated with ursodeoxycholic acid intake. CONCLUSION: In this cohort of infants with extrahepatic biliary atresia, ursodeoxycholic acid was not shown to be effective, and its use was associated with a plethora of hepatic and extrahepatic complications.
Authors: Mary Elizabeth M Tessier; Sanjiv Harpavat; Ross W Shepherd; Girish S Hiremath; Mary L Brandt; Amy Fisher; John A Goss Journal: World J Gastroenterol Date: 2014-08-28 Impact factor: 5.742
Authors: Magd A Kotb; Ahmed Kotb; Sahar Talaat; Sherif M Shehata; Nabil El Dessouki; Ahmed A ElHaddad; Gamal El Tagy; Haytham Esmat; Sameh Shehata; Mohamed Hashim; Hanan A Kotb; Hanan Zekry; Hesham M Abd Elkader; Sherif Kaddah; Hend E Abd El Baky; Nabil Lotfi Journal: Medicine (Baltimore) Date: 2022-09-30 Impact factor: 1.817
Authors: Magd Ahmed Kotb; Dalia Mosallam; Christine William Shaker Basanti; Sally Talaat Mostafa El Sorogy; Ahmed M Badr; Hend El Hosainy Abd El Baky; Iman Hassan Draz Journal: Medicine (Baltimore) Date: 2020-02 Impact factor: 1.817